*For ELISA, the criterion for a positive response was a value of 3 SD above the mean of the Week 26 placebo group read-outs (n = 40) where read-outs are the natural logarithm-transformed averages of t
BackgroundImmunomodulatory/immunosuppressive activity of multiple sclerosis (MS) disease modifying therapies (DMTs) might affect immune responses to SARS-CoV-2 exposure or vaccination in patients with